1. Home
  2. VRAX vs SOBR Comparison

VRAX vs SOBR Comparison

Compare VRAX & SOBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • SOBR
  • Stock Information
  • Founded
  • VRAX 2013
  • SOBR 2004
  • Country
  • VRAX United Kingdom
  • SOBR United States
  • Employees
  • VRAX N/A
  • SOBR N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • SOBR Newspapers/Magazines
  • Sector
  • VRAX Health Care
  • SOBR Consumer Discretionary
  • Exchange
  • VRAX Nasdaq
  • SOBR Nasdaq
  • Market Cap
  • VRAX 4.4M
  • SOBR 4.9M
  • IPO Year
  • VRAX 2022
  • SOBR N/A
  • Fundamental
  • Price
  • VRAX $0.60
  • SOBR $3.33
  • Analyst Decision
  • VRAX Strong Buy
  • SOBR
  • Analyst Count
  • VRAX 1
  • SOBR 0
  • Target Price
  • VRAX $3.00
  • SOBR N/A
  • AVG Volume (30 Days)
  • VRAX 1.4M
  • SOBR 14.7K
  • Earning Date
  • VRAX 01-01-0001
  • SOBR 11-13-2025
  • Dividend Yield
  • VRAX N/A
  • SOBR N/A
  • EPS Growth
  • VRAX N/A
  • SOBR N/A
  • EPS
  • VRAX N/A
  • SOBR N/A
  • Revenue
  • VRAX $6,331.00
  • SOBR $301,400.00
  • Revenue This Year
  • VRAX $217,274.83
  • SOBR N/A
  • Revenue Next Year
  • VRAX N/A
  • SOBR N/A
  • P/E Ratio
  • VRAX N/A
  • SOBR N/A
  • Revenue Growth
  • VRAX N/A
  • SOBR 73.21
  • 52 Week Low
  • VRAX $0.52
  • SOBR $2.41
  • 52 Week High
  • VRAX $3.62
  • SOBR $193.50
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 36.69
  • SOBR 46.91
  • Support Level
  • VRAX $0.54
  • SOBR $3.09
  • Resistance Level
  • VRAX $0.59
  • SOBR $3.49
  • Average True Range (ATR)
  • VRAX 0.06
  • SOBR 0.21
  • MACD
  • VRAX 0.00
  • SOBR 0.01
  • Stochastic Oscillator
  • VRAX 29.92
  • SOBR 57.38

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).

About SOBR SOBR Safe Inc.

Sobr Safe Inc provides non-invasive technology to quickly and humanely identify the presence of alcohol in individuals. Its technologies are integrated within robust and scalable data platform, producing statistical and measurable user and business data. It developed the scalable, patent-pending ea4 software platform for non-invasive alcohol detection and identity verification, a solution that has current and potential applications. It generates revenue through various combinations of software products and services which include the sale of cloud-based software solutions, detection and data collection hardware devices, and cloud-based data reporting and analysis services.

Share on Social Networks: